TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF U.S. DERMATOLOGY DRUGS MARKET 15
1.4 LIMITATION 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 PRODUCTS LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 VENDOR SHARE ANALYSIS 28
2.10 SECONDARY SOURCES 29
2.11 ASSUMPTIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 32
5 MARKET OVERVIEW 44
5.1 DRIVERS 46
5.1.1 INCREASING PREVALENCE OF SKIN DISEASES 46
5.1.2 RISING SPENDING ON HEALTHCARE 47
5.1.3 GROWING AWARENESS FOR DIAGNOSTICS AND TREATMENT OF SKIN DISEASES 50
5.2 RESTRAINTS 51
5.2.1 STRINGENT REGULATIONS FOR DERMATOLOGY DRUGS 51
5.2.2 HIGH COST OF DERMATOLOGY DRUGS 55
5.3 OPPORTUNITIES 58
5.3.1 EXTENSIVE R&D ACTIVITIES IN DERMATOLOGY DRUGS 58
5.3.2 INCREASING INVESTMENT IN BIOLOGICS AND BIOSIMILARS 60
5.4 CHALLENGE 66
5.4.1 SIDE EFFECTS ASSOCIATED WITH DERMATOLOGY DRUGS 66
6 U.S. DERMATOLOGY DRUGS MARKET, BY DRUG CLASS 69
6.1 OVERVIEW 70
6.2 CORTICOSTEROIDS 71
6.2.1 BETAMETHASONE 71
6.2.2 HYDROCORTISONE 71
6.2.3 TRIAMCINOLONE 71
6.2.4 FLUOCINOLONE 71
6.2.5 CLOBETASOL PROPIONATE 71
6.2.6 OTHERS 72
6.3 ANTIFUNGAL DRUGS 73
6.4 SYNTHETIC 73
6.4.1 CLOTRIMAZOLE 73
6.4.2 MICONAZOLE 73
6.4.3 OTHERS 73
6.5 IMIDAZOLES 74
6.5.1 KETOCONAZOLE 74
6.5.2 CLONAZEPAM 74
6.5.3 OTHERS 74
6.6 OTHERS 74
6.7 IMMUNOSUPPRESSIVE DRUGS 75
6.7.1 TACROLIMUS 75
6.7.2 PIMECROLIMUS 75
6.7.3 METHOTREXATE 75
6.7.4 CYCLOSPORINE 75
6.7.5 OTHERS 75
6.8 MONOCLONAL ANTIBODIES 76
6.8.1 ADALIMUMAB 76
6.8.2 INFLIXIMAB 76
6.8.3 SECUKINUMAB 76
6.8.4 USTEKINUMAB 76
6.8.5 OTHERS 76
6.9 RETINOIDS 77
6.9.1 ACITRETIN 77
6.9.2 ADAPALENE 77
6.9.3 ISOTRETINOIN 77
6.9.4 OTHERS 77
6.10 ANTIBIOTICS AGENT 78
6.10.1 DOXYCYCLINE 78
6.10.2 RETAPAMULIN 78
6.10.3 DELAFLOXACIN 78
6.10.4 MINOCYCLINE 78
6.10.5 MUPIROCIN 78
6.10.6 OTHERS 78
6.11 ANTIVIRAL AGENTS 79
6.11.1 ACYCLOVIR 79
6.11.2 FAMCICLOVIR 79
6.11.3 VALACYCLOVIR 79
6.11.4 OTHERS 79
6.12 ANTIHISTAMINES AGENTS 80
6.12.1 CYPROHEPTADINE 80
6.12.2 DIPHENHYDRAMINE 80
6.12.3 HYDROXYZINE 80
6.12.4 OTHERS 80
6.13 OTHERS 80
7 U.S DERMATOLOGY DRUGS MARKET, BY DRUG TYPE 81
7.1 OVERVIEW 82
7.2 BRANDED 83
7.3 GENERICS 83
8 U.S DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE 84
8.1 OVERVIEW 85
8.2 PRESCRIPTION BASED DRUGS 86
8.3 OVER-THE-COUNTER DRUGS 86
9 U.S. DERMATOLOGY DRUGS MARKET, BY INDICATION 87
9.1 OVERVIEW 88
9.2 INFECTIOUS SKIN DISEASE 89
9.2.1 BACTERIAL 89
9.2.1.1 CELLULITIS 89
9.2.1.2 IMPETIGO 89
9.2.1.3 ERYSIPELAS 89
9.2.1.4 ERYTHRASMA 90
9.2.1.5 OTHERS 90
9.2.2 VIRAL 90
9.2.2.1 COLD SORES 90
9.2.2.2 MEASLES 90
9.2.2.3 CHICKENPOX 90
9.2.2.4 VIRAL WARTS 90
9.2.2.5 OTHERS 90
9.2.3 FUNGAL 91
9.2.3.1 TINEA VERSICOLOR 91
9.2.3.2 TINEA PEDIS 91
9.2.3.3 ONYCHOMYCOSIS 91
9.2.3.4 OTHERS 91
9.3 INFLAMMATORY/AUTOIMMUNE DISORDERS 92
9.3.1 PSORIASIS 92
9.3.2 ECZEMA 92
9.3.3 OTHERS 92
9.4 PIGMENTATION DISORDERS 92
9.4.1 HYPERPIGMENTATION 93
9.4.1.1 MELASMA 93
9.4.1.2 SOLAR LENTIGINES 93
9.4.1.3 OTHERS 93
9.4.2 HYPOPIGMENTATION 93
9.4.2.1 VITILIGO 93
9.4.2.2 POSTINFLAMMATORY HYPOPIGMENTATION 94
9.4.2.3 OTHERS 94
9.5 SKIN CANCER 94
9.5.1 BASAL CELL CARCINOMA (BCC) 94
9.5.2 SQUAMOUS CELL CARCINOMA (SCC) 94
9.5.3 MELANOMA 94
9.6 OTHERS 94
10 U.S DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION 95
10.1 OVERVIEW 96
10.2 TOPICAL 97
10.2.1 SEMI-SOLID TOPICAL 97
10.2.1.1 OINTMENTS 97
10.2.1.2 CREAMS 97
10.2.1.3 LOTIONS 97
10.2.1.4 GELS 98
10.2.1.5 PASTE 98
10.2.2 LIQUID TOPICAL 98
10.2.2.1 SOLUTIONS 98
10.2.2.2 SUSPENSION 98
10.2.3 SOLID TOPICAL 98
10.2.3.1 POWDERS 99
10.2.3.2 SUPPOSITORIES 99
?
10.3 ORAL 99
10.3.1 TABLETS 99
10.3.2 CAPSULES 99
10.3.3 SOLUTION 99
10.3.4 PARENTAL 100
10.3.5 SUBCUTANEOUS 100
10.3.6 INTRAVENOUS 100
10.3.7 INTRAMUSCULAR 100
10.3.8 OTHERS 100
11 U.S. DERMATOLOGY DRUGS MARKET, BY END USER 101
11.1 OVERVIEW 102
11.2 HOMECARE 103
11.3 HOSPITALS 103
11.4 DERMATOLOGY CLINICS 103
11.5 OTHERS 103
12 U.S. DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL 104
12.1 OVERVIEW 105
12.2 RETAIL PHARMACY 106
12.3 HOSPITALS PHARMACY 106
12.4 ONLINE PHARMACY 106
12.5 OTHERS 106
13 U.S DERMATOLOGY DRUGS MARKET, COMPANY LANDSCAPE 107
14 COMPANY PROFILES 108
14.1 ABBVIE INC. 108
14.1.1 COMPANY SNAPSHOT 108
14.1.2 REVENUE ANALYSIS 109
14.1.3 PRODUCT PORTFOLIO 109
14.1.4 RECENT DEVELOPMENTS 110
14.2 JOHNSON & JOHNSON SERVICES, INC. 111
14.2.1 COMPANY SNAPSHOT 111
14.2.2 REVENUE ANALYSIS 112
14.2.3 PRODUCT PORTFOLIO 112
14.2.4 RECENT DEVELOPMENTS 113
?
14.3 GLAXOSMITHKLINE PLC. 113
14.3.1 COMPANY SNAPSHOT 113
14.3.2 REVENUE ANALYSIS 114
14.3.3 PRODUCT PORTFOLIO 114
14.3.4 RECENT DEVELOPMENT 114
14.4 ELI LILLY AND COMPANY 115
14.4.1 COMPANY SNAPSHOT 115
14.4.2 REVENUE ANALYSIS 116
14.4.3 PRODUCT PORTFOLIO 116
14.4.4 RECENT DEVELOPMENTS 117
14.5 PFIZER INC. 117
14.5.1 COMPANY SNAPSHOT 117
14.5.2 REVENUE ANALYSIS 118
14.5.3 PRODUCT PORTFOLIO 118
14.5.4 RECENT DEVELOPMENTS 119
14.6 ALMIRALL, S.A. 119
14.6.1 COMPANY SNAPSHOT 119
14.6.2 REVENUE ANALYSIS 120
14.6.3 PRODUCT PORTFOLIO 120
14.6.4 RECENT DEVELOPMENT 121
14.7 BIOFRONTERA AG 121
14.7.1 COMPANY SNAPSHOT 121
14.7.2 REVENUE ANALYSIS 122
14.7.3 PRODUCT PORTFOLIO 122
14.7.4 RECENT DEVELOPMENTS 122
14.8 GALDERMA LABORATORIES, L.P. 124
14.8.1 COMPANY SNAPSHOT 124
14.8.2 PRODUCT PORTFOLIO 124
14.8.3 RECENT DEVELOPMENT 124
14.9 GLENMARK PHARMACEUTICALS LIMITED 125
14.9.1 COMPANY SNAPSHOT 125
14.9.2 REVENUE ANALYSIS 126
14.9.3 PRODUCT PORTFOLIO 126
14.9.4 RECENT DEVELOPMENTS 127
14.10 LEO PHARMA A/S 128
14.10.1 COMPANY SNAPSHOT 128
14.10.2 REVENUE ANALYSIS 128
14.10.3 PRODUCT PORTFOLIO 129
14.10.4 RECENT DEVELOPMENTS 129
?
14.11 MAYNE PHARMA GROUP LIMITED 130
14.11.1 COMPANY SNAPSHOT 130
14.11.2 REVENUE ANALYSIS 131
14.11.3 PRODUCT PORTFOLIO 131
14.11.4 RECENT DEVELOPMENTS 132
14.12 MELINTA THERAPEUTICS, INC. - THE ANTIBIOTICS COMPANY 133
14.12.1 COMPANY SNAPSHOT 133
14.12.2 PRODUCT PORTFOLIO 133
14.12.3 RECENT DEVELOPMENTS 133
14.13 MYLAN N.V. 134
14.13.1 COMPANY SNAPSHOT 134
14.13.2 REVENUE ANALYSIS 135
14.13.3 PRODUCT PORTFOLIO 135
14.13.4 RECENT DEVELOPMENTS 136
14.14 NOVARTIS AG 137
14.14.1 COMPANY SNAPSHOT 137
14.14.2 REVENUE ANALYSIS 138
14.14.3 PRODUCT PORTFOLIO 138
14.14.4 RECENT DEVELOPMENTS 139
14.15 SUN PHARMACEUTICAL INDUSTRIES LTD. 140
14.15.1 COMPANY SNAPSHOT 140
14.15.2 REVENUE ANALYSIS 141
14.15.3 PRODUCT PORTFOLIO 141
14.15.4 RECENT DEVELOPMENT 142
14.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. 143
14.16.1 COMPANY SNAPSHOT 143
14.16.2 REVENUE ANALYSIS 144
14.16.3 PRODUCT PORTFOLIO 144
14.16.4 RECENT DEVELOPMENT 145
14.17 TOLMAR PHARMACEUTICALS, INC. 145
14.17.1 COMPANY SNAPSHOT 145
14.17.2 PRODUCT PORTFOLIO 145
14.17.3 RECENT DEVELOPMENT 146
14.18 UCB S.A., BELGIUM 146
14.18.1 COMPANY SNAPSHOT 146
14.18.2 REVENUE ANALYSIS 147
14.18.3 PRODUCT PORTFOLIO 147
14.18.4 RECENT DEVELOPMENT 147
?
15 QUESTIONNAIRE 148
16 RELATED REPORTS 151